Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells

Nucl Med Biol. 2002 Oct;29(7):729-39. doi: 10.1016/s0969-8051(02)00332-3.

Abstract

The cellular expression of the sodium iodide symporter (NIS) has been shown to confer iodide-concentrating capacity in non-thyroid cell types. We examined the role of NIS in the uptake of the alpha-particle emitting radiohalide [(211)At]astatide in the UVW human glioma cell line transfected to express NIS. [(211)At]Astatide uptake is shown to be NIS-dependent, with characteristics similar to [(131)I]iodide uptake. These studies suggest [(211)At]astatide as a possible alternative radionuclide to [(131)I]iodide for NIS-based endoradiotherapy, and provide a model for the study of [(211)At]astatide behavior at a cellular level.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Astatine / pharmacokinetics*
  • Dose-Response Relationship, Drug
  • Glioma / metabolism*
  • Humans
  • Iodine Radioisotopes / pharmacokinetics*
  • Methimazole / administration & dosage
  • Perchlorates / administration & dosage
  • Radiopharmaceuticals / pharmacokinetics
  • Reference Values
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Sodium Compounds / administration & dosage
  • Symporters / metabolism*
  • Transfection
  • Tumor Cells, Cultured / metabolism

Substances

  • Iodine Radioisotopes
  • Perchlorates
  • Radiopharmaceuticals
  • Sodium Compounds
  • Symporters
  • sodium-iodide symporter
  • Methimazole
  • sodium perchlorate
  • Astatine